Therapeutic inhibitors for the treatment of dry eye syndrome

References

• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017 Jul;15(3):276–283. PubMed PMID: 28736335.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren’s syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999 Sep;19(3):201–211. PubMed PMID: 10487957; eng.
   PubMed Web of Science ®Google Scholar
• Oliveira HF, de Souza TR, Carvalho CN, et al. Serologic profile and clinical markers of Sjogren syndrome in patients with rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jun;119(6):628–635. PubMed PMID: 25956216. DOI:10.1016/j.oooo.2015.02.479
   PubMed Web of Science ®Google Scholar
• El-Shereef RR, Mohamed AS, Hamdy L. Ocular manifestation of systemic lupus erythematosus. Rheumatol Int. 2013 Jun;33(6):1637–1642. PubMed PMID: 22202921. DOI:10.1007/s00296-011-2296-x
   PubMed Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens. 2014 Jul;40(4):248–256. PubMed PMID: 25390549; PubMed Central PMCID: PMCPMC4231828. DOI:10.1097/ICL.0000000000000042
   PubMed Web of Science ®Google Scholar
• Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012 May;31(3):271–285. PubMed PMID: 22426080; PubMed Central PMCID: PMCPMC3334398. DOI:10.1016/j.preteyeres.2012.02.003
   PubMed Web of Science ®Google Scholar
• Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3671–3679. PubMed PMID: 19324847. DOI:10.1167/iovs.08-2689
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017 Jul;15(3):438–510. PubMed PMID: 28736340. DOI:10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007 Apr ;5(2): 75–92. PubMed PMID: 17508116.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Slomovic AR. Sjogren syndrome. Compr Ophthalmol Update. 2007 Jul-Aug;8(4):205–212. PubMed PMID: 17999834.
   PubMedGoogle Scholar
• Baker OJ, Camden JM, Rome DE, et al. P2Y2 nucleotide receptor activation up-regulates vascular cell adhesion molecule-1 [corrected] expression and enhances lymphocyte adherence to a human submandibular gland cell line. Mol Immunol. 2008 Jan;45(1):65–75. PubMed PMID: 17599409; PubMed Central PMCID: PMCPMC2064040. DOI:10.1016/j.molimm.2007.05.009
   PubMed Web of Science ®Google Scholar
• Schrader AM, Camden JM, Weisman GA. P2Y2 nucleotide receptor up-regulation in submandibular gland cells from the NOD.B10 mouse model of Sjogren’s syndrome. Arch Oral Biol. 2005 Jun;50(6):533–540. PubMed PMID: 15848146. DOI:10.1016/j.archoralbio.2004.11.005
   PubMed Web of Science ®Google Scholar
• Wilson SE, Liang Q, Kim WJ. Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2185–2190. PubMed PMID: 10476782.
   PubMed Web of Science ®Google Scholar
• Tanioka H, Kuriki Y, Sakamoto A, et al. Expression of the P2Y(2) receptor on the rat ocular surface during a 1-year rearing period. Jpn J Ophthalmol. 2014 Nov;58(6):515–521. PubMed PMID: 25179431. DOI:10.1007/s10384-014-0342-4
   PubMed Web of Science ®Google Scholar
• Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc. 2001 Jun;76(6):593–599. PubMed PMID: 11393497. DOI:10.4065/76.6.593
   PubMed Web of Science ®Google Scholar
• Le Q, Ge L, Li M, et al. Comparison on the vision-related quality of life between outpatients and general population with dry eye syndrome. Acta Ophthalmol. 2014 Mar;92(2):e124–32. PubMed PMID: 23901943. DOI:10.1111/aos.12204
   PubMed Web of Science ®Google Scholar
• Deschamps N, Ricaud X, Rabut G, et al. The impact of dry eye disease on visual performance while driving. Am J Ophthalmol. 2013 Jul;156(1):184–189 e3. PubMed PMID: 23706501. DOI:10.1016/j.ajo.2013.02.019
   PubMed Web of Science ®Google Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011 Apr;30(4):379–387. PubMed PMID: 21045640. DOI:10.1097/ICO.0b013e3181f7f363
   PubMed Web of Science ®Google Scholar
• Yamada M, Mizuno Y, Shigeyasu C. Impact of dry eye on work productivity. Clinicoecon Outcomes Res. 2012;4:307–312. PubMed PMID: 23091391; PubMed Central PMCID: PMCPMC3471464. DOI:10.2147/CEOR.S36352
   PubMedGoogle Scholar
• Utine CA, Bicakcigil M, Yavuz S, et al. Tear osmolarity measurements in dry eye related to primary Sjogren’s syndrome. Curr Eye Res. 2011 Aug;36(8):683–690. PubMed PMID: 21780917. DOI:10.3109/02713683.2011.571357
   PubMed Web of Science ®Google Scholar
• Baudouin C. Dry eye: an unexpected inflammatory disease. Arch Soc Esp Oftalmol. 2001 Apr;76(4):205–206. PubMed PMID: 11340508.
   PubMedGoogle Scholar
• Colligris B, Crooke A, Huete-Toral F, et al. An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opin Pharmacother. 2014 Jul;15(10):1371–1390. PubMed PMID: 24773445. DOI:10.1517/14656566.2014.914492
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017 Jul;15(3):575–628. PubMed PMID: 28736343. DOI:10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Sy A, O’Brien KS, Liu MP, et al. Expert opinion in the management of aqueous deficient Dry Eye Disease (DED). BMC Ophthalmol. 2015;15(1):133. PubMed PMID: 26462481. DOI:10.1186/s12886-015-0122-z
   PubMed Web of Science ®Google Scholar
• Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 2005 Sep;31(5):186–193. PubMed PMID: 16163009.
   PubMedGoogle Scholar
• Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006 Aug;7(8):675–678. PubMed PMID: 16845723; PubMed Central PMCID: PMCPMC1533759. DOI:10.1631/jzus.2006.B0675
   PubMedGoogle Scholar
• Rajpal RK, Digby D, D’Aversa G, et al. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther. 2011 Jun;27(3):305–308. PubMed PMID: 21574815. DOI:10.1089/jop.2010.0182
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999 Apr;106(4):811–816. PubMed PMID: 10201607. DOI:10.1016/S0161-6420(99)90171-9
   PubMed Web of Science ®Google Scholar
• McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Safety. 2002;25(1): 33–55. PubMed PMID: 11820911; eng.
   PubMed Web of Science ®Google Scholar
• Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjogren’s syndrome. Chonnam Med J. 2015 Apr;51(1):26–32. PubMed PMID: 25914877; PubMed Central PMCID: PMCPMC4406991. DOI:10.4068/cmj.2015.51.1.26
   PubMedGoogle Scholar
• van Walsem A, Pandhi S, Nixon RM, et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015 Mar 19;17:66. PubMed PMID: 25879879; PubMed Central PMCID: PMCPMC4411793. DOI:10.1186/s13075-015-0554-0
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1–4):85–94. PubMed PMID: 17164136. DOI:10.1016/j.prostaglandins.2006.05.019
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Srinivasan BD. Anti-inflammatory effects of ketoprofen in rabbit corneal epithelial wound model. Exp Eye Res. 1985 Sep;41(3):267–273. PubMed PMID: 4065249.
   PubMed Web of Science ®Google Scholar
• Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001 May;108(5):936–944. PubMed PMID: 11320025; eng.
   PubMed Web of Science ®Google Scholar
• Kawahara A, Utsunomiya T, Kato Y, et al. Comparison of effect of nepafenac and diclofenac ophthalmic solutions on cornea, tear film, and ocular surface after cataract surgery: the results of a randomized trial. Clinical Ophthalmology (Auckland, NZ). 2016;10:385–391. PubMed PMID: 27019091; PubMed Central PMCID: PMCPmc4786065. eng. DOI:10.2147/opth.s101836
   PubMed Web of Science ®Google Scholar
• Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 2000 Mar;19(2):145–147. PubMed PMID: 10746444; eng.
   PubMed Web of Science ®Google Scholar
• Aragona P, Di Pietro R. Is it safe to use topical NSAIDs for corneal sensitivity in Sjogren’s syndrome patients? Expert Opin Drug Saf. 2007 Jan;6(1):33–43. PubMed PMID: 17181450. DOI:10.1517/14740338.6.1.33
   PubMed Web of Science ®Google Scholar
• de Smet MD, Nussenblatt RB. Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin. 1993 Fall;33(4):31–45. PubMed PMID: 8258496; eng.
   PubMedGoogle Scholar
• Nussenblatt RB. The use of cyclosporine in ocular inflammatory disorders. Transplant Proc. 1988 Jun;20(3 Suppl 4):114–121. PubMed PMID: 3289201; eng.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016 Jun 10;26(4):287–296. PubMed PMID: 27055414; eng. DOI:10.5301/ejo.5000779
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000 Apr;107(4):631–639. PubMed PMID: 10768324.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Integrating restasis into the management of dry eye. Int Ophthalmol Clin. 2006 Fall;46(4): 101–103. PubMed PMID: 17060796. DOI:10.1097/01.iio.0000212137.85298.98
   PubMedGoogle Scholar
• du Toit LC, Pillay V, Choonara YE, et al. Ocular drug delivery - a look towards nanobioadhesives. Expert Opin Drug Deliv. 2011 Jan;8(1):71–94. PubMed PMID: 21174606. DOI:10.1517/17425247.2011.542142
   PubMed Web of Science ®Google Scholar
• Agarwal P. Rupenthal ID. Modern approaches to the ocular delivery of cyclosporine A. Drug Discov Today. 2016 Jun;21(6):977–988. PubMed PMID: 27080149. DOI:10.1016/j.drudis.2016.04.002
   PubMed Web of Science ®Google Scholar
• Shen Y, Ling X, Jiang W, et al. Formulation and evaluation of cyclosporin A emulgel for ocular delivery. Drug Deliv. 2015;22(7):911–917. PubMed PMID: 24401095. DOI:10.3109/10717544.2013.861883
   PubMed Web of Science ®Google Scholar
• Eroglu YI. A comparative review of Haute Autorite de Sante and National Institute for Health and Care Excellence health technology assessments of ikervis(R) to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes. PubMed PMID: 28839524; PubMed Central PMCID: PMCPMC5560409 J Mark Access Health Policy. 2017;51:1336043. DOI: 10.1080/20016689.2017.1336043
   PubMedGoogle Scholar
• Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S40–5. PubMed PMID: 8811062.
   PubMedGoogle Scholar
• Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, et al. Treatment of Sjogren’s syndrome dry eye using 0.03% tacrolimus eye drop: prospective double-blind randomized study. Contact Lens Anterior Eye. 2015 Oct;38(5):373–378. PubMed PMID: 25956572. DOI:10.1016/j.clae.2015.04.004
   PubMed Web of Science ®Google Scholar
• Liendo VL, Vola ME, Barreiro TP, et al. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. Arq Bras Oftalmol. 2017 Jul-Aug;80(4):211–214. PubMed PMID: 28954018. DOI:10.5935/0004-2749.20170052
   PubMed Web of Science ®Google Scholar
• Sanz-Marco E, Udaondo P, Garcia-Delpech S, et al. Treatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops. J Ocul Pharmacol Ther. 2013 Oct;29(8):776–783. PubMed PMID: 23947579; PubMed Central PMCID: PMCPMC3787325. DOI:10.1089/jop.2012.0265
   PubMed Web of Science ®Google Scholar
• sRainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015 Oct;23(5):231–269. PubMed PMID: 26246395; eng. DOI:10.1007/s10787-015-0239-y
   PubMed Web of Science ®Google Scholar
• Biasi D, Caramaschi P, Carletto A, et al. Combined drug therapy in recent-onset rheumatoid arthritis. Evaluation after 1 year of treatment]. Recenti Prog Med. 1998 Jan;89(1):14–17. PubMed PMID: 9549387; ita.
   PubMedGoogle Scholar
• Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996 Jun;5(Suppl 1):S11–5. PubMed PMID: 8803904; eng.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013 Oct;43(2):264–272. PubMed PMID: 23481418; eng. DOI:10.1016/j.semarthrit.2013.01.001
   PubMed Web of Science ®Google Scholar
• Stelton CR, Connors DB, Walia SS, et al. Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol. 2013 Jun;32(6):895–898. PubMed PMID: 23515601; eng. DOI:10.1007/s10067-013-2226-2
   PubMed Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016 Apr;14(2):207–215. PubMed PMID: 26807723. DOI:10.1016/j.jtos.2016.01.001
   PubMed Web of Science ®Google Scholar
• Abidi A, Shukla P, Ahmad A. Lifitegrast: A novel drug for treatment of dry eye disease. J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):194–198. PubMed PMID: 28163544; PubMed Central PMCID: PMCPMC5242036. DOI:10.4103/0976-500X.195920
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Stern M, Zhang S, et al. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease. J Ocul Pharmacol Ther. 2017 Jan/Feb;33(1):5–12. PubMed PMID: 27906544; PubMed Central PMCID: PMCPMC5240001. DOI:10.1089/jop.2016.0105
   PubMed Web of Science ®Google Scholar
• Paton DM. Lifitegrast: first LFA-1/ICAM-1 antagonist for treatment of dry eye disease. Drugs Today (Barc). 2016 Sep;52(9):485–493. PubMed PMID: 27883115. DOI:10.1358/dot.2016.52.9.2542066
   PubMed Web of Science ®Google Scholar
• Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083–1094. PubMed PMID: 27354762; PubMed Central PMCID: PMCPMC4910612. DOI:10.2147/OPTH.S110557
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016 Jun;35(6):741–748. PubMed PMID: 27055211; PubMed Central PMCID: PMCPmc4859202. eng.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014 Feb;121(2):475–483. PubMed PMID: 24289915. DOI:10.1016/j.ophtha.2013.09.015
   PubMed Web of Science ®Google Scholar
• Maliartchouk S, Feng Y, Ivanisevic L, et al. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol. 2000 Feb;57(2):385–391. PubMed PMID: 10648649.
   PubMed Web of Science ®Google Scholar
• Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res. 2011 Oct;93(4):503–512. PubMed PMID: 21726552. DOI:10.1016/j.exer.2011.06.014
   PubMed Web of Science ®Google Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275–1285. PubMed PMID: 23836957; PubMed Central PMCID: PMCPMC3699314. DOI:10.2147/OPTH.S44688
   PubMedGoogle Scholar
• Anglade E, Yatscoff R, Foster R, et al. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opin Investig Drugs. 2007 Oct;16(10):1525–1540. PubMed PMID: 17922618. DOI:10.1517/13543784.16.10.1525
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012 Jan;130(1):90–100. PubMed PMID: 22232476; PubMed Central PMCID: PMCPMC3677724. DOI:10.1001/archophthalmol.2011.364
   PubMedGoogle Scholar
• Okanobo A, Chauhan SK, Dastjerdi MH, et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012 Jul;154(1):63–71. PubMed PMID: 22541929; PubMed Central PMCID: PMCPMC3378826. DOI:10.1016/j.ajo.2012.01.034
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011 Apr 07;117(14):3720–3732. PubMed PMID: 21304099; PubMed Central PMCID: PMCPmc3083294. eng. DOI:10.1182/blood-2010-07-273417
   PubMed Web of Science ®Google Scholar
• Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci USA. 2013 Mar 5;110(10):3913–3918. PubMed PMID: 23431173; PubMed Central PMCID: PMCPMC3593924. DOI:10.1073/pnas.1217996110
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Tubridy KL, Agahigian J, et al. A phase 2 exploratory study of a novel interleukin-1 receptor inhibitor (EBI-005) in the treatment of moderate-to-severe allergic conjunctivitis. Eye Contact Lens. 2015 May;41(3):145–155. PubMed PMID: 25915834. DOI:10.1097/ICL.0000000000000152
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Martel JR, Sall K, et al. Multicenter study of a novel topical interleukin-1 receptor inhibitor, isunakinra, in subjects with moderate to severe dry eye disease. Eye Contact Lens. 2016 Jul 27 PubMed PMID: 27466718; eng. DOI:10.1097/icl.0000000000000276.
   Web of Science ®Google Scholar
• Amparo F, Dastjerdi MH, Okanobo A, et al. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013 Jun;131(6):715–723. PubMed PMID: 23599118; PubMed Central PMCID: PMCPMC4167802. DOI:10.1001/jamaophthalmol.2013.195
   PubMed Web of Science ®Google Scholar
• Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced Mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016 Feb;44(2):275–281. PubMed PMID: 26584195; PubMed Central PMCID: PMCPmc5378312. eng. DOI:10.1097/ccm.0000000000001402
   PubMed Web of Science ®Google Scholar
• Doughty MJ. On the prescribing of oral doxycycline or minocycline by UK optometrists as part of management of chronic Meibomian Gland Dysfunction (MGD). Cont Lens Anterior Eye. 2016 Feb;39(1):2–8. PubMed PMID: 26347083; eng. DOI:10.1016/j.clae.2015.08.002
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z, Carter B, et al. Interventions for rosacea. Cochrane Database Syst Rev. 2015 Apr 28;4:CD003262. PubMed PMID: 25919144. DOI:10.1002/14651858.CD003262.pub5
   PubMed Web of Science ®Google Scholar
• Solomon A, Rosenblatt M, Li D, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Am J Ophthalmol. 2000 Nov;130(5):688. PubMed PMID: 11078862; eng.
   PubMedGoogle Scholar
• Foulks GN, Borchman D. Meibomian gland dysfunction: the past, present, and future. Eye Contact Lens. 2010 Sep;36(5):249–253. PubMed PMID: 20724853. DOI:10.1097/ICL.0b013e3181ef0d37
   PubMed Web of Science ®Google Scholar
• Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res. 2003 Apr;76(4):417–420. PubMed PMID: 12634106; eng.
   PubMed Web of Science ®Google Scholar
• Fox RI. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjogren’s syndrome. Adv Exp Med Biol. 2002;506(Pt B): 1107–1116. PubMed PMID: 12614037.
   PubMedGoogle Scholar
• Brimhall J, Jhaveri MA, Yepes JF. Efficacy of cevimeline vs. pilocarpine in the secretion of saliva: a pilot study. Spec Care Dentist. 2013 May-Jun;33(3):123–127. PubMed PMID: 23600983. DOI:10.1111/scd.12010
   PubMedGoogle Scholar
• Masunaga H, Ogawa H, Uematsu Y, et al. Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. Eur J Pharmacol. 1997 Nov 19;339(1):1–9. PubMed PMID: 9450610; eng.
   PubMed Web of Science ®Google Scholar
• Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjogren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004 Jul;138(1):6–17. PubMed PMID: 15234277. DOI:10.1016/j.ajo.2004.02.010
   PubMed Web of Science ®Google Scholar
• Carracedo G, Crooke A, Guzman-Aranguez A, et al. The role of dinucleoside polyphosphates on the ocular surface and other eye structures. Prog Retin Eye Res. 2016 Nov;55:182–205. PubMed PMID: 27421962. DOI:10.1016/j.preteyeres.2016.07.001
   PubMed Web of Science ®Google Scholar
• Pintor J, Sanchez-Nogueiro J, Irazu M, et al. Immunolocalisation of P2Y receptors in the rat eye. Purinergic Signal. 2004 Dec;1(1):83–90. PubMed PMID: 18404404; PubMed Central PMCID: PMCPMC2096566. DOI:10.1007/s11302-004-5072-5
   PubMedGoogle Scholar
• Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea. 2004 Nov;23(8):784–792. PubMed PMID: 15502479; eng.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012 Jul;29(7):579–589. PubMed PMID: 22843206; eng. DOI:10.1007/s12325-012-0033-9
   PubMed Web of Science ®Google Scholar
• Jin SW, Min JS. Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome. Jpn J Ophthalmol. 2016 Feb 12. PubMed PMID: 26873225. DOI:10.1007/s10384-016-0430-8
   PubMed Web of Science ®Google Scholar
• Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. Clin Ophthalmol. 2015;9:865–872. PubMed PMID: 26028958; PubMed Central PMCID: PMCPMC4440420. DOI:10.2147/OPTH.S69486
   PubMed Web of Science ®Google Scholar
• Fukuoka S, Arita R. Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes. Ocul Surf. 2017 Mar 28. PubMed PMID: 28363586; eng. DOI:10.1016/j.jtos.2017.03.005
   PubMed Web of Science ®Google Scholar
• Itoh S, Itoh K, Shinohara H. Regulation of human corneal epithelial mucins by rebamipide. Curr Eye Res. 2014 Feb;39(2):133–141. PubMed PMID: 24073690. DOI:10.3109/02713683.2013.834939
   PubMed Web of Science ®Google Scholar
• Haruma K, Ito M. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003 Jul;18(Suppl 1):153–159. PubMed PMID: 12925154.
   PubMedGoogle Scholar
• Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003 Jul;18(Suppl 1):8–13. PubMed PMID: 12925136.
   PubMedGoogle Scholar
• Tanaka H, Fukuda K, Ishida W, et al. Rebamipide increases barrier function and attenuates TNFalpha-induced barrier disruption and cytokine expression in human corneal epithelial cells. Br J Ophthalmol. 2013 Jul;97(7):912–916. PubMed PMID: 23603753. DOI:10.1136/bjophthalmol-2012-302868
   PubMed Web of Science ®Google Scholar
• Kohashi M, Ishimaru N, Arakaki R, et al. Effective treatment with oral administration of rebamipide in a mouse model of Sjogren’s syndrome. Arthritis Rheum. 2008 Feb;58(2):389–400. PubMed PMID: 18240266; eng. DOI:10.1002/art.23163
   PubMed Web of Science ®Google Scholar
• Urashima H, Takeji Y, Okamoto T, et al. Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbits. J Ocul Pharmacol Ther. 2012 Jun;28(3):264–270. PubMed PMID: 22304618. DOI:10.1089/jop.2011.0147
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013 Jun;120(6):1158–1165. PubMed PMID: 23490326; eng. DOI:10.1016/j.ophtha.2012.12.022
   PubMed Web of Science ®Google Scholar
• Kato K, Takashima Y, Matsunaga K, et al. Effect of topical rebamipide on conjunctival goblet cell recovery after vitrectomy. Sci Rep. 2016 Jan 14;6:19516. PubMed PMID: 26762482; PubMed Central PMCID: PMCPmc4725884. eng. DOI:10.1038/srep19516
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Keith MS, Sudharshan L, et al. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015;9:1719–1730. PubMed PMID: 26396495; PubMed Central PMCID: PMCPMC4577273. DOI:10.2147/OPTH.S89700
   PubMed Web of Science ®Google Scholar
• Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017 Jul;15(3):539–574. PubMed PMID: 28736342. DOI:10.1016/j.jtos.2017.05.001
   PubMed Web of Science ®Google Scholar